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Highlights 
 
 The present study shows that mammography screening is able to 
detect the majority of breast tumors at a small size and lymph node 
negative in familial breast cancer 
 Tumor characteristics and projected survival are better than in a 
comparison unscreened familial cohort 
 Radiation dose in 35-39 year olds is not higher than in older women 
 
Outstanding questions: Longer term follow up of larger numbers is required to assess 
overall survival and any impact of radiation dose on future primary risk. Health 
Economic analysis should determine whether mammography screening in this age 
group should be limited to the high risk group or include those at moderate risk. 
Abstract (words 250) 
 
Background:Many women who are at increased risk of breast cancer due to a mother 
or sister diagnosed with breast cancer aged under 40 do not currently qualify for 
surveillance before 40 years of age. There are almost no available data to assess 
whether mammography screening aged 35-39 years would be effective in this group 
of women or cost effective. 
Methods:A cohort screening study (FH02) with annual mammography was devised 
for women aged 35-39 to assess the sensitivity and screening performance and 
potential survival of women with identified tumours. 
Findings: 2899 women were recruited from 12/2006-12/2015. These women 
underwent 12086 annual screening mammograms and were followed for 13365.8 
years. A total of 55 breast cancers in 54 women occurred during the study period 
(one bilateral) with 50 cancers (49 women) (15 CIS) adherent to the screening.  
Eighty percent (28/35) of invasive cancers were ≤2cm and 80% also lymph node 
negative. Invasive cancers diagnosed in FH02 were significantly smaller than  the 
comparable (POSH-unscreened prospective) study group (45% (131/293) ≤2cm in 
POSH vs 80% (28/35) in FH02 p<0.0001), and were less likely to be lymph-node 
positive (54% (158/290, 3 unknown) in POSH vs 20% (7/35) in FH02: p=0.0002. 
Projected and actual survival were also better than POSH. Overall radiation dose was 
not higher than in an older screened population at mean dose on study per standard 
sized breast of 1.5mGy. 
Interpretation: Mammography screening aged 35-39 years is likely to be as effective 
as in women at increased breast cancer risk aged 40-49 years.   
 
 
 
 
Introduction (4123 words) 
 
Women aged less than 50 years are not eligible for National Breast Screening 
Programmes, but those who have significant breast cancer family histories are 
frequently referred for regular mammography as a secondary prevention measure1.  
These women may have breast cancer incidence substantially higher than the 
population risk of women in their fifties who qualify for the national programme in 
the UK. A study to evaluate annual mammography in women aged 40-49 (FH01 
study)2,3 showed a projected mortality advantage for annual mammography 
surveillance compared to age matched women with no screening based on tumour 
characteristics at diagnosis4. No such prospective evaluation has yet been carried out 
in women aged 35-39 who are currently invited for screening in many clinics. The 
design of mammographic surveillance evaluation studies is problematic. The 
feasibility study which preceded FH01 included surveys of clinical staff managing 
women at familial risk, and indicated that there was insufficient equipoise to conduct 
randomised controlled trials2,3. As a result, the FH01 study was designed as a single-
arm cohort study, estimating the likely surveillance benefit on breast cancer 
mortality from both internal modelling and comparison with other contemporary 
cohorts not undergoing such surveillance3.  
 
The UK NICE guidelines5 indicated a gap in knowledge of the value of mammography 
in high-risk women aged <40, and a clear research need in this area. NICE stated 
that any such screening in women aged <40 should only be performed as part of 
research to evaluate such an intervention. The aim of the current study was to 
provide such an evaluation. A review of the literature by NICE for the 2013 guidance5 
did not reveal any significant evidence for screening with mammography without MRI 
<40 years of age and a literature search in December 2017 still revealed no 
significant subsequent publications. Although a small proportion of women in the 
moderate/high-risk categories (~5%) are eligible for MRI screening in the UK in line 
with NICE guidance,  mainly because of carrying  BRCA1/2 pathogenic variants, the 
vast majority of those with a familial risk <40 years of age do not currently qualify 
for health service surveillance. Approximately 3% of women <40 are at moderate or 
high-risk of breast cancer5,6 and at least half of these come forward with concerns6. 
The FH01 study established a likely beneficial effect on mortality from breast cancer 
in the 40-50 age group as estimated from tumour size, node status and grade of the 
tumours diagnosed in the women recruited3,4 and led to recommendations supporting 
annual surveillance in this age group5. It was deemed unlikely that a project in the 
35-39 age group would be able to recruit sufficient numbers to give a precise 
estimate of these endpoints. We therefore proposed to base evaluation on the 
accuracy of the screening test. This approach was used in four UK trials of breast 
screening in the last 20-years: the US one-view/two-view trial, the DMIST study of 
digital mammography, the MARIBS trial of MRI in very high-risk women and the 
CADET study of computer-aided detection in breast screening.7-10 Thus there is a 
precedent for deducing and project the effect on clinical outcomes from the observed 
results in terms of early detection. The rationale is that if proof of principle of early 
detection is already established, regimens which achieve this early detection with 
high degrees of accuracy are likely to be effective3. If this can be shown to be of the 
same order as in the FH01 and UK age trials, which both studied the effects of 
annual mammography from age 40-4911, one could have some confidence that the 
surveillance would have similar effects as in those studies. A retrospective audit of 
surveillance in three centres in the UK showed that results were similar to FH01 in 
terms of screening accuracy with similar size and lymph node status in those 
undergoing annual mammography1. Here we present results of the multicentre 
prospective FH02 study. 
  
  
Methods 
Unaffected women with a family history of breast cancer (usually affecting at least one 
first degree relative) meeting the criteria in table 1 and aged 35-39 years were 
eligible for trial entry. Women in the retrospective arm of FH021 were only eligible if 
they were still aged 35-39 and without breast cancer. Women were screened with 
mammography annually. 
Thirty four centres contributed prospective screening data as part of the FH02 study  
 The aims and purpose of the study were:-  
1.  To estimate, in terms of screening accuracy (sensitivity/specificity and stage of 
cancers) the likely benefit of annual mammography in women at increased risk aged 
35-39 by comparison with the accuracy and endpoints observed in the FH01 study 
and the UK Age Trial 
2. To compare the screening accuracy and outcomes between the prospective study with 
strict entry criteria and interventions, to retrospective FH02 with no universal 
standard of eligibility or intervention 
3. To compare the prognostic indicators of the detected tumours and long term patient 
outcome with women with a family history who were not screened in the POSH 
study. The POSH study recruited incident breast cancers in women aged 40 or below 
in the UK from 2000-200712,13. 
4. To estimate the likely benefit, if any, of this mammographic activity- in order to inform 
policy as to whether it should continue in the UK 
 
The prospective study involved formal design and control, including risk criteria to 
ensure that the enrolled population undergoing surveillance was at sufficient breast 
cancer risk to achieve a worthwhile balance of benefit and harm of the intervention. 
Annual mammography was the study standard. Data were collected on screening 
episode outcomes, additional diagnostic activity in those recalled for further 
assessment, biopsy and detection rates, active follow-up to ascertain interval 
cancers, and full clinico-pathological data on the cancers diagnosed. The prospective 
study collected the same data items as in FH01 allowing a detailed comparison with 
FH013. The prospective collection of the pathology data allowed an informative 
comparison with the tumours in the POSH study which has complete tumour 
ascertainment12. Thus, the prospective study allowed formal evaluation addressing 
all 4 study aims. 
 
The original protocol indicated recruitment of 2,800 women between age 35-39, with 
a family history of breast cancer, and who fulfilled at least one of the criteria in Table 
1. 
 
Satisfying one of these inclusion criteria gives an individual a ten year risk of 
developing breast cancer below age 40 of ≥1.5%13-17. This accords with information 
from the retrospective arm of FH02 in Manchester where 47 cancers in this age 
group occurred at an incidence of 4.77 per 1,0001.  
 
Exclusion criteria for FH02 included: 
Inability or refusal to give written informed consent; pregnancy; women below the 
age of 35 or above the age of 39;  a previous history of breast cancer or ductal 
carcinoma in situ or bilateral risk reducing mastectomy;  contraindication to annual 
X-rays and if a cancer is detected by MRI and not mammography. 
 
 
Women already under surveillance, including those contributing to the retrospective 
study, were eligible, as were women newly presenting to genetic/family history 
clinics. Detailed information on the family history of each individual in the study was 
recorded at baseline. Standard outcomes included attendance; normal/abnormal 
outcome; investigations and outcome of subsequent assessment and any surgical 
intervention, for all those recruited. In addition, clinical and pathological data were 
collected on each cancer diagnosed at each screening episode and on interval 
cancers. The radiation dose from mammography was recorded, if available, in order 
to assess likely risks from additional radiation exposure.  The value recorded was the 
mean glandular dose (MGD) per image, either as displayed by the mammography 
equipment or as calculated.  
 
Endpoints and analyses: The primary outcomes expected at the end of the study 
period were as follows: 
1. Detection rates by screening round (incidence or prevalence). This is the number of 
cancers detected per thousand women screened.  
2. Number of interval cancers by risk stratum.  
3. Programme and test sensitivity, the latter estimated taking mean sojourn time (the 
duration of the preclinical screen-detectable period) into account 18. 
4. Number of recalls, including benign, per cancer detected including bilateral. 
5. Number of surgery/surgical biopsy cases per cancer detected. 
6. Cancers diagnosed by size, node status, grade and receptor status. 
 
As part of the data analysis, all of the above were compared with the corresponding 
outcomes in FH01, taking account of differences in underlying incidence in the two 
cohorts (see below). Likely future fatality from breast cancer as assessed by the 
numbers of screen-detected and interval cancers, was compared with that expected 
if there were no screening, taking into account lead time and length bias and 
potential overdiagnosis19-23. Tumour prognostic indicators and outcomes were 
compared with unscreened women with breast cancers aged 35-40 years in the UK 
POSH study with a similar family history diagnosed 2000-2008. The analyses were 
performed separately including and excluding ductal carcinoma in situ (DCIS) cases.  
 
Study size: For simplicity, we based our power/sample size calculations on the 
comparison of a measure of sensitivity between this study and the UK Age Trial. The 
sensitivity measure proposed was the programme sensitivity (S) in an annual 
screening regime. If CS is the number of screen-detected cancers and CI the number 
of interval cancers diagnosed within one year of a negative screen, we assume CS to 
be binomially distributed with denominator CS+CI. In the Age Trial, S was 65%22. To 
have 90% power detect a significant S in our population being 20% lower in absolute 
terms (i.e. 45%), we would need 65 cancers screen-detected plus interval cancers 
(thosepresenting symptomatically within one year) in total. This total would also give 
a 95% confidence interval on S of no more than 12% in either direction. To calculate 
the number of screens necessary to give 65 cancers, we note that in younger women 
incidence screens and prevalence screens have approximately the same detection 
rates23. We expect N x I x MST x ST cancers at screening, where N is the number 
screened, I the underlying incidence MST the mean sojourn time and ST the test 
sensitivity24. With S= 45%, we therefore need just over double the above product to 
be equal to 65. Assuming ST=0.8, MST=1.5, and an incidence of 2-4 per thousand 
per year (3-7 times the population incidence for this age group), we would need 
approximately 10,000 screens. We therefore aimed to collect data on this total 
number of screens. As a failsafe, we aimed to recruit 2,800 subjects, with screening 
for five years. 
 
Risk categories 
The risk thresholds for trial entry were those used in current NICE guidance which 
defines moderate risk as 17-29% lifetime risk of breast cancer or calculated 3% 10-
year risk aged 40 years. The Tyrer-Cuzick algorithm was used as a single 
reproducible objective measure of 10-year risk. The high-risk category was defined 
as ≥8% 10-year risk with age set at 40 years regardless of age at entry. Similarly 3-
7.99% 10-year risk was defined as moderate and <3% near average risk. 
Cancer verification 
Breast cancers were confirmed from each centre using hospital pathology reports. In 
addition a search was made in Dec 2017 on the National Cancer Registry to ensure 
that all interval cancers were identified. 
 
Statistical methods 
Comparison of tumour attributes between FH02 and POSH and between FH02 and 
FH01 was done using chi-squared tests. Projected breast cancer deaths based on the 
tumour attributes in FH02 was compared with that expected in the absence of 
screening using a similar method as in FH014, but simplified in that we select our 
comparison group as those cancers in POSH diagnosed in women satisfying the risk 
criteria of FH02. Thus, we estimated the projected relative mortality as: 
   
  
  
 
Where d1 is the predicted fatality rate from the Nottingham Prognostic Index of the 
tumours in FH02, and d2 the corresponding rate for the POSH cases in this age group 
meeting the FH02 risk criteria. This is simpler than the formula used for FH01 as 
there is no necessity to adjust for different risk status of the two populations. 
The expected number of breast cancers overall and in risk categories was obtained 
from the Tyrer-Cuzick model by summating each woman’s expected breast cancer 
risk cumulative hazard from study entry mammogram to date of breast cancer 
diagnosis or 30/06/2016 whichever was earlier (unless censored for death or risk 
reducing mastectomy). Exact Poisson confidence intervals were calculated for 
incidence rate and to compare the observed with expected number of cancers. FH02 
received research ethics approval in 2005 (MREC Reference No: 05/MRE02/67) 
Results  
Prospective study 
Thirty four UK centres recruited a total of 2899 women aged 35-39 years between 
Dec 2006 and Dec 2015. These women underwent 12086 annual screening 
mammograms (9751 digital; 2335 analogue) and were followed for a total of 
13365.8 years to time of censoring. A total of 55 breast cancers (54 women) 
occurred during the study period (one bilateral) including 12-months follow up until 
Dec 2016 to allow for potential interval cancers (cancer registration was checked in 
December 2017). Overall 447 other women were withdrawn from the screening 
aspect of the study:, 24 due to change of genetic risk status, 193 failed to attend 
and were removed from local screening programme 4 had died (non-cancer), 40 
moved away, 100 became pregnant, and 22 women underwent risk reducing 
mastectomy during the study period with two (9%) having occult breast cancers and 
64 due to miscellaneous reasons.  
 
 
Overall, approximately half of the women received their first ever mammogram in 
FH02 (n=1410 -2.1 per 1000 women) with 1438 having had previous mammography 
and 51 unknown. There were 3 prevalent cancers in the study (2.1 per 1000 women 
who had undergone previous mammography).  
 
Table 2 shows breast cancer incidence by Tyrer-Cuzick risk category and 
prevalent/incident status, for all cancers and for those diagnosed up to age 41. There 
were 34 incident cancers detected at screening mammography (including two from a 
bilateral case) and 13 interval cancers (11 with previous digital mammogram) as 
such 72% (34/47) of women with post prevalent cancers were screen detected. Two 
of the interval cancers were found at risk reducing mastectomy as a 17mm grade 2 
DCIS and a 3mm grade 1 invasive cancer.  
 
 
Four cancers occurred more than 18-months from the last screen in women who had 
defaulted on screening and a further large cancer was identified symptomatically in a 
woman consented to the study who had not received a baseline mammogram. These 
five cases were excluded from the estimation of screening parameters and 
comparison with POSH. Programme sensitivity is conservatively estimated as 
34/(13+34) = 72%. Mean sojourn time was estimated as 1.8 years and test 
sensitivity as 93%.  
Tumour pathology at diagnosis compared with POSH study participants without 
surveillance who had similar family history to FH01 and FH02 diagnosed between 
2000-2008 is shown in table 3. The FH02 invasive cancers were significantly smaller 
than the POSH symptomatic controls (45% [131/293] ≤2cm in POSH vs 80% 
[28/35] in FH02; Table 3). POSH controls were significantly more likely to be lymph 
node positive (54% [158/290, 3 unknown] in POSH vs 20% [7/35] in FH02.)Women 
had a higher rate of breast cancer mortality in POSH than FH02 but a Kaplan Meier 
analysis (Figure 1) did not confirm statistical significance and statistical power was 
limited (log rank chi square is 2.94, p=0.086; HR 4.8 (95% CI 0.7 –34.8).  There 
was only one death in FH02 at 2.78 years with overall follow up of 2.7-11.2 years 
(mean=5.35 years). There were similar rates of DCIS in prospective FH02 compared 
to retrospective FH02 and FH01 (Table 3).  
 
Breast cancer incidence 
The overall incidence including follow up to a maximum age of 49 years was 3.9 per 
1000 excluding prevalent screen detected cancers (Table 2). Restricting follow up to 
the 41st birthday allowing for incident cancers in the 41st year (if screened at 40 
women would only have a prevalent scan that year) incidence rates were a little 
below the NICE threshold for 10-year risk in the moderate-risk group at 2.7 per 
1000, but above in the high-risk categories (10.3). Using a 3% 10-year threshold at 
entry for the moderate risk group this reduced the number eligible to 1188 women 
(60% of total) with a rate of 3.3% from 10 breast cancers to age 41 years with 9.9 
expected. Those 499 women with average risk had overall rates of only 2.3 per 1000 
and only 1.2 in the 35-40 age group.  Overall, 47.5 breast cancers were expected 
using Tyrer-Cuzick with 52 occurring after prevalence (O/E 1.09, 95%CI 0.83-1.43).  
 
Breast biopsy and recall 
A total of 729/12086 mammograms (6%) resulted in a recall. The recall rate was 
9.65% (278/2898) in first round and 4.9% (451/9188) subsequently. Overall there 
were 191 breast biopsies (core or open) for 37 screen detected cancers, therefore 
18.3% (35/191) of biopsies resulted in a cancer diagnosis. Thus, there were 20 
recalls per cancer screen detected, 19 false positives per screen detected cancer, and 
5 biopsies per cancer screen detected.  
 
Radiation dose 
Radiation dose was available from 25/34 centres, with values recorded for a total of 
8585/12086 examinations (71%).  The distribution of dose values from two centres 
was inconsistent with real values, probably due to recording errors, and these were 
excluded from further analysis.  Of the remaining 8278, a subset of 4666 
examinations were of women in the age range 35-39 years.  For this subset, the 
mean breast thickness was 54mm and the mean MGD for a mixture of craniocaudal 
and mediolateral oblique views was 1.5mGy.  This dose is slightly lower than the 
average values of 1.6 to 2.0 mGy reported in the FH01 study4.   It is consistent with 
the reported mean values of 2.0 mGy and 1.5 mGy for analogue and digital 
mammography equipment respectively used in the NHS Breast Screening 
Programme to screen women aged 47 years and older25.  As expected, larger breasts 
received higher doses and this variation was similar to that reported for the older 
age group (Figure 2).  These results indicate that doses to women aged 35-39 in 
FH02 were comparable with those in the FH01 study and the NHS Breast Screening 
Programme. 
 
Genetic testing 
Systematic genetic testing was only carried out in the Manchester cohort. Of 22 
breast cancers 6 had a pathogenic BRCA1 variant, 4 in BRCA2 with 11 having no 
pathogenic variant identified and one remaining untested. Four BRCA1 carriers had 
been undergoing concurrent MRI but three of the lesions were also detected at 
mammography and the third was the 17mm DCIS found at risk reducing 
mastectomy. Only 19/854 (2.2%) in Manchester were known BRCA carriers at entry 
and an additional 16 at some point after entry. Of 23 other centres that submitted 
BRCA1/2 data only 28/1593 (1.76%) were know pathogenic variant carriers. 
Projected mortality 
Of the breast cancer cases in POSH in the age group of FH02, 264 satisfied the FH02 
risk criteria. Using the NPI formula for ten year survival as in FH01, we estimate that 
the FH02 cases will have 79% ten year survival and the POSH cases will have 71% 
ten-year survival. Thus we estimate a relative mortality of 21/29=0.72, with a 95% 
CI of (0.49-1.07), that is a 28% reduction in mortality associated with the 
surveillance activity in FH02. The study was not powered for this analysis, hence it 
does not reach statistical significance. As a sensitivity analysis, assuming that due to 
lead time, length bias etc the hazard of death for the FH02 cases is underestimated 
by 10%, this would give an expected 77% survival in the FH02 cases, and a RR of 
0.79, a 21% reduction in mortality. 
 
Discussion 
The present study shows that programme and test sensitivity (72% and 93%) of 
mammography screening in women aged 35-39 years of age at moderate and high-
risk of breast cancer are similar to those in women aged 40-49 years in the FH01 
study4. The overall and projected survival is substantially better than in comparable 
women aged 35-40 in the POSH study who did not undergo screening.13 Overall 10-
year survival in POSH was 73·4% (67·4–78·5) for BRCA1/2 pathogenic variant 
carriers versus 70·1% (67·7–72·3) for BRCA negative women13. This is very similar 
to our projected 71% survival from tumour characteristics. In contrast we estimate 
10-year survival in invasive cases from FH02 to be 77-79%. Assessing only the 
invasive cases will underestimate the potential for saving lives from mammography 
screening. Whilst diagnosis of screen detected in situ disease is considered by many 
to be an ‘overdiagnosis’ this is very unlikely to be the case in women under 50-years 
of age. Long term follow up after cessation of screening in women <50 showed no 
eventual excess of cancers.26,27 In particular most untreated high grade DCIS would 
relapse or transform to high grade invasive disease within 10-years if left untreated28 
and the majority of our DCIS were high grade (61.5%-8/13). Therefore successful 
identification of CIS in this age group is likely to prevent further deaths from invasive 
disease. 
 
There are, of course, legitimate concerns regarding radiation exposure in young 
women that might induce a malignancy that may not otherwise occur. A meta-
analysis revealed a non-significant increased risk of breast cancer among women at 
high-risk of breast cancer exposed to low-dose radiation OR=1.3, (0.9–1.8)29. With 
exposure to a mean of ≥5 exposures giving an OR=1.8 (1.1–3.0). The authors 
concluded that a careful approach was needed when using low-dose radiation in 
women at high-risk of breast cancer. We recently presented data showing no strong 
evidence for an increased risk in women receiving ≥5 mammograms before 40 years 
of age30. We have shown that radiation exposure in FH02 is not higher in this young 
aged group of women than in older women in routine screening in the UK. It is also 
reassuring that radiation doses are similar to older women in the UK national 
screening programme25, and we do not appear to be doing excessive harm from 
overdiagnosis. 
 
NICE guidelines in the UK currently recommend screening moderate and high risk 
women aged 40-49 years of age with annual mammography[5]. A case could now be 
made to extend this to those aged 35-39 years. NICE did carry out a health 
economic evaluation to confirm that such screening aged 40-49 years with a 3% 10-
year risk was cost effective based on the results of FH014. A large proportion of 
women who reach moderate risk because a single first degree relative 
(mother/sister) has been diagnosed with breast cancer aged <40 years, would not 
meet a 3% 10-year risk until just before age 40 years using Tyrer-Cuzick v.8. 
Nevertheless a life saved in a 38 year old would provide an extra 10 years of life 
expectancy compared to a similar woman aged 48 years and thus with similar 
potential gains in cure rates the cost effectiveness in 35-39 year olds may be met 
with a lower rate threshold. Otherwise women could become eligible once their 10-
year risk reach 3% in the 35-39 year period, although this may mean that sisters 
with different reproductive risk factors gain entry to screening at different ages. 
 
It could also be argued that testing all women at moderate or greater risk of breast 
cancer for BRCA1/2 pathogenic variants would have identified a large proportion of 
those who developed cancer in the 35-40 age group. The Manchester data suggest 
that perhaps half of the cancers could have occurred in BRCA1/2 carriers. However, 
none of these were from the moderate risk group. Currently only a small proportion 
of women at NICE defined high risk are covered by the NHS National Breast 
Screening Programme ‘Higher risk’ MRI screening. As such opening mammography 
based screening to those at high and moderate risk based on just NICE algorithm  
would potentially benefit 3-4% of the population with this rising to 10-18% if risk 
algorithms incorporating mammographic density and single nucleotide polymorphism 
polygenic risk scores (SNP-PRS) were utilised6, 31. These may identify over 40% of 
the breast cancers in this age group if results can be replicated from the older 
screened population31. Screening of a multigene panel including high risk genes such 
as BRCA1 and BRCA2 will lift some women into an MRI screening category, but even 
with a negative BRCA1/2 test women with strong family histories still have high 
incidence rates aged <50 years32 Indeed testing of a SNP-PRS is likely to provide a 
better risk stratification in the familial population than panel testing.33 
 
There are some limitations to our study. The size is small, but was deliberately 
powered to assess whether the screening performance and sensitivity of the FH01 
study could be replicated. A major strength is that the study involved 34 screening 
units showing that results can be replicated across many sites. 
 
In conclusion we have shown that mammography screening in women at moderate 
and high risk of breast cancer aged 35-39 years has high sensitivity and detects the 
majority of cancer at low stage with good survival prospects. The Tyrer-Cuzick risk 
algorithm appears to predict cancer risk accurately and could be used as a 
‘gatekeeper’ for entry to early mammography. 
 
Acknowledgments 
FH02 was funded by two grants from Breast Cancer Now (2013MayPR026). DGE and 
AH are supported by the NIHR Manchester Biomedical Research centre (IS-BRC-
1215-20007). The funders had no role in paper design, data collection, data analysis, 
interpretation or writing of the paper. 
 
Contributions 
literature search,  
Evans DG, Burch A,  Duffy S 
study design,  
Evans DG, Thomas S,  Howell A,  Wilson M, R Fox,  Sibbering DM, Moss S, Wallis MG,  
Duffy S 
data collection,  
Evans DG, Thomas S, Caunt J,  Roberts L, Eccles DM,  
data analysis,  
Evans DG,  Brentnall AR, Eccles DM, Duffy S 
data interpretation,  
Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, Howell A,  Wilson M, 
R Fox, Hillier S, Sibbering DM, Moss S, Wallis MG, Eccles DM, Duffy S 
writing 
Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, Howell A,  Wilson M, 
R Fox, Hillier S, Sibbering DM, Moss S, Wallis MG, Eccles DM, Duffy S 
FH02 Study Group authors 
   
Airedale NHS Foundation Trust Claire Murphy Helen Hothersall 
Ardmillan Screening Centre, Edinburgh Dr Lesley Smart Lynda Luke 
Birmingham Mrs Simerjit Rai  Jenny Williamson 
Bradford Dr Richard Linforth Helen Robertshaw 
BTW Cardiff 
Mr Dean Phillips and 
teams at screening 
centres across Wales Dr Mark Rogers 
BTW Llandudno  Dr Carrie Pottinger 
BTW Singleton  Dr Alex Murray 
Burton, Queen's Hospital Dr Nick Luft Jacqueline Elliott 
Chester 
Mrs Claudia Harding 
MacKean Mary Aldous 
Craigavon Area Hospital, Southern 
Health and Social Care Trust. Northern 
Ireland Dr Cathy Farnon Leanne McCourt 
Derby Mr Mark Sibbering Wendy Chorley 
Great Ormond Street/Barts   Dr Vian Salih Dr Lucy Side 
Grantham District Hospital Mr Potdar  Lynn Osborne 
Hope Hospital, Salford Mr. S. Chatterjee Kay Goulden 
Kettering 
Mr Rashed 
Margaret Turns Joanne Walsh 
Leeds Mr Philip Turton Mrs Sue Hartup 
Leicester Dr Julian Barwell Christine Masterson 
Leighton Hospital, Crewe Tracey Hale Vanessa Adamson 
Altnagelvin Hospital, Londonderry Dr Michael Reilly Celia Diver-Hall 
Newcastle Dr Alex Henderson Irene Jobson 
Northwick Park Hospital Mr William Teh  
Nottinghamie Pottinger 
Mr R.D Macmillan  
Lisa Brock Nicky Scott 
Pilgrim Hospital Boston Lincs Mr Potdar   Isobel Thomas 
Portsmouth Carmel Sheppard Tracey Dobson 
Royal Devon & Exeter 
Di Cameron 
Pauline Sibley Mary Davies 
Royal Liverpool University Hospital Sue Holcombe Laura Price 
Royal Marsden Hospital, London 
Mr Gerald Gui 
Dr Janet Self 
Catherine Montgomery 
Suzanne England 
Royal United Hospital, Bath Dr Diana Dalgliesh Katherine Knight 
St Helen’s &  Knowsley NHS Trust.  Riccardo Audisio  Michelle Robinson 
Southend University Hospital  Mr Neil Rothnie Anne Mcpherson 
Royal Cornwall Hospital, Truro. Dr K Stepp  Helen Maguire 
Ulster Hospital Mr Stephen Kirk Mrs Jennifer Foreman 
Manchester Universities Hospital Rosemary Greenhalgh Sally Cole  
Foundation Trust Jenny Affen 
Karen Tricker 
Julia Wiseman 
 
University Hospitals Coventry & 
Warwickshire NHS Trust Celia Lewis  
Wirral University Hospital Teaching 
Hospital 
Ms M. Shaughnessy 
Alison McGenity Julie McEntee 
 
References 
1. Evans DG, Thomas S, Caunt J, Roberts L, Howell A, Wilson M, Fox R, 
Sibbering DM, Moss S, Wallis MG, Eccles DM; FH02 study group, Duffy S Evans DG, 
Thomas S, Caunt J, Roberts L, Howell A, Wilson M, Fox R, Sibbering DM, Moss S, 
Wallis MG, Eccles DM; FH02 study group, Duffy S Mammographic surveillance in 
women aged 35-39 at enhanced familial risk of breast cancer (FH02). Fam Cancer. 
2014;13(1):13-21 
2. Mackay J, Rogers C, Fielder H, et al. Development of a protocol for evaluation 
of mammographic surveillance services in women under 50 with a family history of 
breast cancer. J Epidemiol Biostat 2001; 6: 365-9.  
3. FH01 management committee, steering committee and collaborators. The 
challenge of evaluating annual mammography screening for young women with a 
family history of breast cancer. J Med Screening. 2006; 13:177-82. 
4. FH01 collaborative teams. Mammographic surveillance in women younger 
than 50 years who have a family history of breast cancer: tumour characteristics and 
projected effect on mortality in the prospective, single-arm, FH01 study. Lancet 
Oncol. 2010;11:1127-34. 
5. McIntosh A, Shaw C, Evans G, et al (2013 updated 2017). Clinical Guidelines 
and Evidence Review for The Classification and Care of Women at Risk of Familial 
Breast Cancer, London: National Collaborating Centre for Primary Care/University of 
Sheffield. NICE guideline CG164.www.nice.org.uk Accessed 27th Dec 2017 
6. Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley 
SM, Wilson M, Ainsworth J, Cuzick J, Buchan I, Donnelly S, Howell A. Breast cancer 
risk in young women in the National Breast Screening Programme: implications for 
applying NICE guidelines for additional screening and chemoprevention. Cancer 
Prevention Research 2014;7(10):993-1001 
7. Wald NJ, Murphy P, Major P, et al, UKCCCR multicentre randomised controlled 
trial of one and two view mammography in breast cancer screening. BMJ 1995; 311: 
1189-93 
8. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital 
versus film mammography for breast cancer screening NEJM 2005; 353: 1773-83 
9. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance 
imaging and mammography of a UK population at high familial risk of breast cancer: 
a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78 
10. Gilbert FJ, Astley SM, Gillan MG, et al. Single reading with computer aided 
detection for screening mammography. NEJM 2008; 359: 1675-84. 
11. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L; Trial Management 
Group. Effect of mammographic screening from age 40 years on breast cancer 
mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006; 
368:2053-60. 
12. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG; POSH 
steering group. Prospective study of Outcomes in Sporadic versus Hereditary breast 
cancer (POSH): study protocol. BMC Cancer. 2007;7:160.  
13. Copson E, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S,  Altman 
DG, Eccles B, Durcan LR, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, 
Dunning AM, Hanby A, Lakhani SR, Eeles R, Gilbert FJ, Hamed H, Hodgeson S, 
Simmonds P, Stanton L, Eccles DM. The impact of germline BRCA mutation on 
outcome in young onset breast cancer - the POSH study. Lancet Oncol 2017; 
 
14. Claus E, Risch N, Thompson WD. Genetic analysis of breast cancer in the 
cancer and steroid hormone study. Am J Human Genet 1991; 48: 232-42. 
15.  Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating 
familial and personal risk factors. Stat Med 2004;23:1111-30 
16.   Amir  E, Evans DG, Shenton  A, Lalloo et al Evaluation of Breast Cancer Risk 
Assessment Packages in the Family History Evaluation and Screening Programme.  J 
Med Genet 2003; 40):807-14 
17. Eccles DM, Evans DGR, Mackay J. Guidelines for a genetic risk based 
approach to advising women with a family history of breast cancer. J Med Genet 
2000: 37:203-9 
18. Day NE, Walter SD. Simplified models of screening for chronic disease: 
estimation procedures from mass screening programmes. Biometrics 1984; 43: 1-
13.Pharoah P, Day NE, Duffy S et al Family history and the risk of breast cancer: a 
systematic review and meta-analysis  Int J Cancer 1997;71:800-809. 
19. Maurice A, Evans DGR, Shenton A, Boggis C, Wilson M, Duffy S, Howell A. The 
Screening of Women Aged Less Than 50 Years at Increased Risk of Breast Cancer By 
Virtue of Their Family History. Eur J Cancer 2006; 42:1385-90 
20. Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A. Surveillance 
of women at increased risk of breast cancer using mammography and clinical breast 
examination: Further evidence of benefit. Int J Cancer. 2012;131:417-25 
21. Day N,  McCann J,  Camilleri-Ferrante C, et.al  Monitoring interval cancers in 
breast screening programmes: the east Anglian experience. Quality Assurance 
Management Group of the East Anglian Breast Screening Programme  Med Screen 
1995; 2: 180-5. 
22. Moss S, Waller M, Anderson TJ, Cuckle H; Trial Management Group. 
Randomised controlled trial of mammographic screening in women from age 40: 
predicted mortality based on surrogate outcome measures. Br J Cancer. 
2005;92:955-60 
23. Bjurstam N, Bjorneld L, Duffy SW et al. The Gothenburg breast screening 
trial: first results on mortality, incidence, and mode of detection for women ages 39-
49 years at randomization Cancer 1997; 80:2091-9. 
24. Paci E, Duffy SW. Modelling the analysis of breast cancer screening 
programmes: sensitivity, lead time and predictive value in the Florence District 
Programme (1975-1986). Int J Epidemiol. 1991 Dec;20:852-8 
25. Young KC, Oduko JM. Radiation doses received in the United Kingdom breast 
screening programme in 2010 to 2012. Br J Radiol 2016; 89: 20150831 
26. Hellquist BN, Duffy SW, Nyström L, Jonsson H. Overdiagnosis in the 
population-based service screening programme with mammography for women aged 
40 to 49 years in Sweden. J Med Screen. 2012;19:14-9. 
27. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW.Effect of 
mammographic screening from age 40 years on breast cancer mortality in the UK 
Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015 
Sep;16(9):1123-1132 
28. Khan S, Epstein M, Lagios MD, Silverstein MJ. Are We Overtreating Ductal 
Carcinoma in Situ (DCIS)? Ann Surg Oncol. 2017;24(1):59-63. 
29. Jansen-van der Weide MC, Greuter MJ, Jansen L, Oosterwijk JC, Pijnappel RM, de 
Bock GH. Exposure to low-dose radiation and the risk of breast cancer among women 
with a familial or genetic predisposition: a meta-analysis. Eur Radiol 2010; 20: 2547–56. 
30. Evans DG, Kotre CJ, Harkness E, Wilson M, Maxwell AJ, Howell A. No strong 
evidence for increased risk of breast cancer 8-26 years after multiple mammograms in 
their 30s in females at moderate and high familial risk. Br J Radiol. 2016;89(1059): 
20150960. 
31. Van Veen E, Brentnall AR, Byers H, Harkness E, Astley S, Sampson S, Howell A, 
Newman W, Cuzick J, Evans DG. Improving classical breast cancer risk prediction with 
single nucleotide polymorphisms and mammographic density. JAMA Oncol 2018; 
4(4):476-482 
32. Evans DGR, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, 
Leach MO, Warren R, Thompson D, Easton DF, Eeles R on behalf of The UK study of MRI 
screening for breast cancer in women at high risk (MARIBS). Eligibility for MRI screening 
in the UK: Effect of strict selection criteria and anonymous DNA testing on breast cancer 
incidence in the MARIBS study. Cancer Epid Biomarkers Prev 2009;18(7):2123-31 
33. Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A; FH-risk study 
Group., Newman WG, Cuzick J. The impact of a panel of 18 SNPs on breast cancer risk in 
women attending a UK familial screening clinic: a case-control study. J Med Genet. 
2017;54(2):111-113. 
 
 
  
Table 1: Eligibility criteria for FH02 
1 first degree (FDR) female - breast cancer <40  
2) 1 FDR - bilateral breast cancer first cancer diagnosed <50;  
3) 2 FDR or 1 FDR and 1 second degree (SDR) female - both with breast cancer <60;  
4) 1 FDR/SDR female - breast and ovarian cancer first cancer diagnosed <60 
5) 2 FDR or 1 FDR and 1 SDR female - breast cancer <60 and ovarian cancer at any 
age; 
6) 3 FDR/SDR degree female - breast or ovarian cancer at any age;  
7)1 first degree male - breast cancer at any age  
8)paternal history of a minimum of 2 SDR (NB. father’s first degree relatives) with 
breast cancer <50 or breast <50 and an ovarian cancer (any age), or paternal 
uncle/grandfather with breast cancer <50 years;  
9) A BRCA1/2 mutation carrier or at least a 1 in 4 risk of carrying a known mutation 
in a family. 
 
Table 2: Breast cancer incidence by Tyrer-Cuzick 10-year risk category in FH02 
Tyrer-Cuzick 
Risks age 40 
High Risk 
8%+  10-year  
Moderate risk  
3-7.9% 10-year 
Average Risk 
<3% 10-year risk  
Total 
Total years 
follow up 
1447.4 9220.0 2572.9 13237.8 
-Number of 
recruits 
344 1977 499 2820 
Breast cancers 
Prevalent 
 1  2 0 3 
Breast cancers 
post prevalent 
13 
 
33 
 
6 52 
Expected T-C 18.8 25 3.7 47.5 
Rate per 1000* 9.0 (95%CI 5.2-
15.5) 
3.6 (95%CI 2.5-
5.1) 
2.3 (95%CI 1.0-
5.2) 
3.9 
(95%CI 
2.9-5.2) 
Recall 
mammograms 90 481 142 713 
Screen detected 
cancers 9 25 3 37 
Ratio of recalls 
to screen 
detected 
cancers 
10:1 19:1 47:1 19:1 
Recalls per year 
of follow up 6.2% 5.2% 5.5% 5.4% 
     
Follow up to age 41 years only 
years follow up 1068.8 6197.3 1609.2 8875.3 
Number of 
recruits 344 1977 499 2820 
Breast cancers 
Prevalent 
 1  2 0 3 
Breast cancers 
Post Prevalent 
11 
 
17 
 
2 
 
30 
 
Expected T-C 12.5 14.8 1.9 29.2 
Rate per 1000* 
10.3 (95%CI 
5.7-18.6) 
2.7 (95%CI 1.6-
4.4) 
1.2 (95%CI 0.2-
4.9) 
3.4 
(95%CI 
2.3-4.9) 
Numbers to be 
screened for 
each screen 
detected cancer 
35-40 years 31 95 322 85 
Intervals 35-40 4 6 1 11 
*Rates exclude prevalent cancers 
 
 
 
 
 
Table 3: Breast cancers identified in the prospective FH02 study compared 
to the POSH study and retrospective FH02 and FH01 
Age at Diagnosis POSH FHpos 
Unscreened 
35-40 (%) 
FH01 40-49 
Prospective 
(%) 
retrospective 
FH02 35-39+ 
(%) 
Prospective 
FH02 35-40         
(%) 
N 293 136 47 50 
Years of diagnosis 2000-2008 2003-2010 1990-2008 2007-2016 
Years follow up 1-12 years 0-7 years 1-12 years 0-9 years 
Histology     
Invasive (%) 293 (100%) 96 (74) 35 (74) 35 (70) 
Grade 1 (% of invasive) 18 (6) 17 (19) 3 (8.6) 6 (17) 
Grade 3 (% of invasive) 177 (60.5) 40 (45) 17 (48.6) 21 (60) 
In-situ (%) 0 not 
included in 
POSH 
34 (26) 12 (26) 15 (30) 
Unknown  6  - 0 
P value compared to 
prospective FH02 
N/a as POSH 
only invasive 
   
 
 
   
Size (in situ excluded) 
N=293 
 
N=87 
 
N=35 
  
N=35 
≤2cm 138 (47) 61/87 (70) 25 (74) 28 (80) 
2-4.9cm 122 (41.5)  8 (23) 6 (18) 
≥5cm 23 (8)  1 (3) 1 (3) 
Unknown 10 9 1 0 
P value  for ≤2cm compared to 
prospective POSH  
  
P<0.0001 
     
Node Involvement 
(in situ excluded) 
N=293 
 
 
N=82 
 
 
N=35 
  
  
N=35 
0 133 (45) 56 (68) 25 (77) 28 (80) 
1-4 110 (38)  7 (23) 5 (15) 
>4 48 (16)  - 2 (6) 
Not sampled/[not known] 3 (1) [14] 3 0  
P value for LN0 compared to 
POSH 
 
Stage 1 of invasive 83 (28%) 
 
 
 
- 
 
 
 
21 (60) 
 P=0.0002 
 
24 (68.5%) 
 
P value POSH ref 
  
   P<0.0001 
Status N=289  N=47 N=49* 
Alive (no metastasis) 204 (70) NK 43 (91) 49 (98) 
Alive (with metastasis) 23 (8)  0 (0) 0 
Died (of disease) 63 (21.5)  4 (9) 1 (2) 
Died (other) 10 (3.5)  0 0 
P value compared to POSH     P=0.0009 
Annual Incidence Rate/ 1000   4.77 3.85 
*one case was bilateral at diagnosis 
+Retrospective FH02 was a survey of previous screening in the same age range prior 
to the launch of FH02 [1]. P value by Chi Square testing 
  
Figure 1: Breast cancer specific survival in invasive cases versus POSH Family 
history positive cases 
 
 
 
 
  
 Figure 2: Mean glandular dose per image as a function of breast thickness.  FH02 refers 
to women aged 35-39 years in the present study and BSP refers to published data for 
older women in the NHS Breast Screening Programme [3].  Error bars show ±2 standard 
errors.   
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